title: [Initial antiretroviral treatment in human immunodeficiency virus-infected patients in Spain: Decisions made in relation to particular immunovirological characteristics (PERFIL-es study)].
abstract: BACKGROUND
  The purpose of Perfil-es study was to identify the proportion of patients starting ARV treatment based on NNRTIs or PI/r, and to identify the variables involved in the therapeutic decision-making in standard clinical practice.
  
  
  METHODS
  An observational retrospective study performed in 65 Spanish hospitals.
  
  
  RESULTS
  Was a total of 1,687 starts: 53% with NNRTI-based regimen and 42% with PI/r, and of the 642 patients analyzed, 72% had a CD4 count<350 cells/μl.
  
  
  CONCLUSIONS
  The initiation of ARV treatment is still late in Spain. NNRTIs are the more frequent choice, although PI/r plays an important role.
authors.affiliation: Servicio Enf. Infecciosas, Hospital Universitario Virgen del Rocío, Sevilla, España. Electronic address: pompeyov@gmail.com.
authors.forename: Pompeyo
authors.initials: P
authors.lastname: Viciana
authors.affiliation: Unidad VIH. Med. Interna, Hospital Xeral Cíes, Vigo, España.
authors.forename: Antonio
authors.initials: A
authors.lastname: Ocampo
authors.affiliation: Medical Affairs Manager, Janssen, Madrid, España.
authors.forename: Henar
authors.initials: H
authors.lastname: Hevia
authors.affiliation: Medical Affairs Manager, Janssen, Madrid, España.
authors.forename: Marta
authors.initials: M
authors.lastname: Palazuelos
authors.affiliation: Medical Affairs Manager, Janssen, Madrid, España.
authors.forename: Francisco
authors.initials: F
authors.lastname: Ledesma
mesh_terms: D019380:Anti-HIV Agents / Q000145:classification / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004359:Drug Therapy, Combination; D004363:Drug Utilization; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors
keywords: Antiretroviral treatment; Human immunodeficiency virus; Inhibidor de la proteasa potenciado con ritonavir; Inhibidor de la transcriptasa inversa no análogo de nucleósidos; Naive; Non-nucleoside reverse transcriptase inhibitors; Protease inhibitors; Tratamiento antirretroviral; Virus de la inmunodeficiencia humana